Peyronie's disease in Spain: a prospective study
Por:
Peinado-Ibarra, F, García-Gómez, B, Alonso-Isa, M, Simón-Rodríguez, C, García-Cardoso, J, Torremadé-Barreda, J, Campos-Juanatey, F, García-Baquero, R, Alvarez-Maestro, M, Fernández-Pascual, E, Martínez-Salamanca, JI, Martínez-Jabaloyas, J, Rosselló-Gayá, M, Chantada, V, Cáceres-Rodríguez, F, Sarquella, J, Ruiz-Castañé, E, Lledó, E, Fernández-Arjona, M, Fiter, L, Cortiñas, JR, Romero-Otero, J
Publicada:
1 ago 2026
Resumen:
Background Peyronie's disease (PD) research has limitations due to heterogeneity in time of presentation, severity, deformity characteristics, and associated conditions.Aim To provide further insight into clinical characteristics of patients, PD treatments and patient perceptions of outcomes in clinical practice in Spain.Methods A total of 601 men from 15 Spanish andrology centers were included in this observational, prospective multicenter cohort study. Enrolled patients (aged >= 18 years with confirmed PD diagnosis, na & iuml;ve to specific therapy and without congenital penile curvature) were evaluated by detailed medical history and physical examination including plaque characteristics and curvature. Sexual function was assessed by the International Index of Erectile Function-5 and the Peyronie's Disease Questionnaire. The characteristics of treatment used for PD as well as patient subjective outcomes were analyzed in cases involving curvature assessments.Outcomes The primary outcome was demographic and clinical characterization of PD patients; secondary outcomes included PD treatment used in clinical practice and patient satisfaction.Results The median age (interquartile range, IQR) was 57 (49.0-63.0) years with a median duration of PD of 12 (6.0-18.0) months. There were 246 (41.6%) patients in the acute phase of the disease. The most common nonsurgical treatments were traction therapy (36.0%), collagenase injections (29.3%), and daily tadalafil (22.7%). The most frequently used surgical technique was penile plication (62.3%) followed by grafting and plaque incision (34.0%). The median Peyronie's Disease Questionnaire and International Index of Erectile Function-5 scores were 19.0 (12.0-28.0) and 18.0 (13.0-22.5), respectively. Curvature assessment was performed in 331 patients, using the Kelami test in 316 (96.0%) or intracavernous injection of a vasoactive agent in 143 (45.5%).Clinical implications Many patients are misdiagnosed, and treatment may take a long time; understanding the profile of PD, as well as satisfaction with real-life treatment outcomes, can aid clinicians in selecting more appropriate treatments.Strengths and Limitations As a free collaborative registry, not all patient data were collected, and therefore not all data were available throughout the study, and a longer follow-up period would have given us more information to compare the pretreatment and post-treatment situations. However, this study provides a description of clinical characteristics of a large real-world cohort of men with PD from a considerable number of sites nationwide.Conclusions We found a wide variety of treatments used in clinical practice, including those with poor evidence of efficacy, which suggests the need for a better understanding of PD for developing the most effective treatment protocol.
Filiaciones:
Peinado-Ibarra, F:
Univ Europea Madrid, Hosp Univ Quiron Ruber Juan Bravo 39, Fac Med, Urol Dept, Madrid 28006, Spain
García-Gómez, B:
Hosp Univ 12 Octubre, Urol Dept, Madrid 28041, Spain
Alonso-Isa, M:
Hosp Univ 12 Octubre, Urol Dept, Madrid 28041, Spain
Simón-Rodríguez, C:
Hosp Univ Fdn Jimenez Diaz, Urol Dept, Madrid 28040, Spain
García-Cardoso, J:
Hosp Univ Fdn Jimenez Diaz, Urol Dept, Madrid 28040, Spain
Torremadé-Barreda, J:
Hosp Clin Barcelona, Urol Dept, Barcelona 08036, Spain
Campos-Juanatey, F:
Hosp Univ Marques Valdecilla, Urol Dept, Santander 39008, Spain
García-Baquero, R:
Hosp Univ Puerta Mar, Urol Dept, Cadiz 11009, Spain
Alvarez-Maestro, M:
Hosp Univ La Paz, Urol Dept, Madrid 28046, Spain
Fernández-Pascual, E:
Univ Francisco Vitoria, Urol Dept, LYX Inst Urol, Madrid 28006, Spain
Martínez-Salamanca, JI:
Univ Francisco Vitoria, Urol Dept, LYX Inst Urol, Madrid 28006, Spain
Martínez-Jabaloyas, J:
Hosp Clin Univ Valencia, Urol Dept, Valencia 46010, Spain
Rosselló-Gayá, M:
Ctr Urol Androl & Med Sexual, Urol Dept, Palma De Mallorca 07010, Illes Balears, Spain
Chantada, V:
Hosp Univ A Coruna CHUAC, Urol Dept, La Coruna 15006, Spain
Cáceres-Rodríguez, F:
Hosp Univ Alava, Urol Dept, Vitoria 01009, Spain
Sarquella, J:
Fdn Puigvert, Urol Dept, Barcelona 08025, Spain
Ruiz-Castañé, E:
Fdn Puigvert, Urol Dept, Barcelona 08025, Spain
Lledó, E:
Hosp Gen Univ Gregorio Maranon, Urol Dept, Madrid 28007, Spain
Fernández-Arjona, M:
Hosp Univ Henares, Urol Dept, Coslada 28822, Madrid, Spain
Fiter, L:
Hosp Univ Severo Ochoa, Urol Dept, Leganes 28914, Madrid, Spain
Cortiñas, JR:
Hosp Univ Rio Hortega, Urol Dept, Valladolid 47012, Spain
Romero-Otero, J:
Hosp Univ 12 Octubre, Urol Dept, Madrid 28041, Spain
gold
|